Stock Analiz

Neuronetics, Inc. STIM

Medical/Dental Instruments · IPO 2018 · data as of November 13, 2026

$1.39Market cap $134M
Open the interactive analysis →

Neuronetics, Inc. (STIM) is a healthcare company listed in the US with a market value of about $134M. In the twelve months to September 30, 2026 it had revenue of $160M and net income of -$23M, a net margin of -14.4%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 25% a year, a 5-year average ROIC of -24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 65% below the current price.

About Neuronetics

Neuronetics is listed in the US and classified in medical/dental instruments, IPO year 2018. Revenue went from $34M in 2016 to $149M in 2025, growth of about 17.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 145% over three years (dilution for shareholders). It spends 4% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.8
P/B7.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-7.1%
Shareholder yield0.0%
Intrinsic value vs. price−65%

Growth and quality

Revenue growth (1 yr)99.2%
Revenue growth (5 yrs, per year)24.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-48.0%
ROIC (5-yr avg.)-23.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$160M$149M$75M$71M$65M$55M$49M$63M$53M$40M$34M
Net income-$23M-$39M-$44M-$30M-$37M-$31M-$27M-$29M-$24M-$16M-$11M
Free cash flow-$10M-$21M-$32M-$34M-$34M-$30M-$29M-$31M-$22M-$12M-$9M
EPS (diluted)$-0.33$-0.59$-1.38$-1.05$-1.38$-1.22$-1.46$-1.58$-2.69$-86.34$-76.95
Net margin-14.4%-26.2%-58.4%-42.3%-57.0%-56.4%-55.8%-46.4%-45.7%-39.7%-32.8%
ROIC—-22.0%-24.8%-25.0%-28.6%-17.5%-27.6%-25.9%-15.4%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $6.00, 332% above the current price; targets range from $5.00 to $7.00; the consensus rating is “Strong buy”; expected EPS is $-0.46 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Neuronetics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 65% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Neuronetics pay a dividend?

Not currently.

Is Neuronetics a good stock to buy?

We do not give buy or sell advice. Neuronetics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.